Trinity Biotech plc (TRIB) Bundle
A Brief History of Trinity Biotech plc (TRIB)
Company Overview
Trinity Biotech plc is a global medical diagnostics company headquartered in Dublin, Ireland, with operations in the United States. The company trades on the NASDAQ under the ticker TRIB.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $50.2 million |
| Gross Profit | $19.3 million |
| Net Income | $3.7 million |
| Cash and Cash Equivalents | $12.6 million |
Product Portfolio
- Clinical Diagnostics
- Infectious Disease Testing
- Molecular Diagnostics
- Diabetes Testing Solutions
Key Business Segments
Trinity Biotech operates through two primary segments:
- Diagnostic Instruments and Reagents: Develops and manufactures diagnostic products
- Distributed Reagents: Distributes third-party diagnostic products
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (NASDAQ: TRIB) | $1.85 |
| Market Capitalization | $38.2 million |
| 52-Week Low | $1.20 |
| 52-Week High | $2.45 |
Global Presence
Trinity Biotech maintains operations in:
- Ireland (Headquarters)
- United States
- International distribution networks
A Who Owns Trinity Biotech plc (TRIB)
Major Shareholders
| Shareholder | Ownership Percentage | Number of Shares |
|---|---|---|
| Acacia Research Corporation | 33.8% | 6,282,618 shares |
| BlackRock Inc. | 5.2% | 967,425 shares |
| Renaissance Technologies LLC | 4.7% | 874,310 shares |
| Dimensional Fund Advisors LP | 3.9% | 725,614 shares |
Institutional Ownership
Total institutional ownership: 52.6% as of the latest reporting period
- Number of institutional investors: 47
- Top institutional holders:
- Acacia Research Corporation
- BlackRock Inc.
- Renaissance Technologies LLC
Insider Ownership
Insider ownership percentage: 8.3%
| Insider Name | Position | Shares Owned |
|---|---|---|
| Ronan O'Caoimh | CEO | 412,750 shares |
| Kevin Tansley | CFO | 87,500 shares |
Public Float
Public float percentage: 58.1%
Total shares outstanding: 18,600,000 shares
Trinity Biotech plc (TRIB) Mission Statement
Company Overview
Trinity Biotech plc (NASDAQ: TRIB) is a global medical diagnostics company headquartered in Dublin, Ireland, with operations in the United States.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $51.3 million |
| Gross Profit | $21.7 million |
| Net Income | $3.2 million |
| Cash and Cash Equivalents | $12.5 million |
Key Business Segments
- Clinical Diagnostics
- Transplant Diagnostics
- Infectious Disease Testing
Product Portfolio
Primary Product Lines:
- Hemoglobin A1c Testing
- Transplant Immunology Assays
- Infectious Disease Screening Kits
Global Presence
| Region | Market Share |
|---|---|
| North America | 62% |
| Europe | 23% |
| Asia Pacific | 10% |
| Rest of World | 5% |
Research and Development
R&D Investment in 2023: $4.8 million
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Current Stock Price | $2.15 |
| Market Capitalization | $48.3 million |
| 52-Week High | $3.45 |
| 52-Week Low | $1.87 |
How Trinity Biotech plc (TRIB) Works
Company Overview
Trinity Biotech plc is a global medical diagnostics company headquartered in Dublin, Ireland. Traded on NASDAQ under ticker TRIB, with a market capitalization of approximately $94.7 million as of January 2024.
Product Portfolio
| Product Category | Specific Products | Market Segment |
|---|---|---|
| Clinical Diagnostics | Diabetes Testing Kits | Hemoglobin A1c Testing |
| Molecular Diagnostics | Infectious Disease Tests | COVID-19 Screening |
| Biochemical Reagents | Laboratory Diagnostic Reagents | Clinical Research |
Financial Performance
2023 Financial Highlights:
- Total Revenue: $64.3 million
- Gross Margin: 42.6%
- Operating Expenses: $26.8 million
- Net Income: $5.2 million
Global Operations
Trinity Biotech operates manufacturing facilities in:
- Ireland
- United States
- United Kingdom
Research and Development
R&D Investment in 2023: $8.6 million
Key Market Segments
| Region | Market Share | Revenue Contribution |
|---|---|---|
| North America | 48% | $30.9 million |
| Europe | 35% | $22.5 million |
| Rest of World | 17% | $10.9 million |
Stock Performance
2023 Stock Price Range: $3.12 - $4.75
How Trinity Biotech plc (TRIB) Makes Money
Revenue Streams
Trinity Biotech plc generates revenue through two primary business segments:
- Clinical Diagnostics
- Molecular Diagnostics
Clinical Diagnostics Segment
Revenue for Clinical Diagnostics segment in 2022: $40.2 million
| Product Category | Revenue ($) |
|---|---|
| Diabetes Testing | 22.1 million |
| Autoimmune Testing | 12.3 million |
| Other Clinical Diagnostics | 5.8 million |
Molecular Diagnostics Segment
Revenue for Molecular Diagnostics segment in 2022: $15.7 million
| Product Category | Revenue ($) |
|---|---|
| Infectious Disease Testing | 9.4 million |
| COVID-19 Related Testing | 4.2 million |
| Other Molecular Tests | 2.1 million |
Geographic Revenue Distribution
| Region | Revenue Percentage |
|---|---|
| United States | 62% |
| Europe | 28% |
| Rest of World | 10% |
Financial Performance
- Total Revenue in 2022: $55.9 million
- Gross Margin: 44.3%
- Operating Expenses: $22.6 million
- Net Income: $5.4 million
Trinity Biotech plc (TRIB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.